Christopher Pagett

Mr. Christopher Pagett

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
AAAne Appelt
Ane Appelt
PAPiotr Andrzejewski
Piotr Andrzejewski
LHLone Hoffmann
Lone Hoffmann
CKColin Kelly
Colin Kelly
CMChrysanthi Michailidou
Chrysanthi Michailidou
MPMarija Popovic
Marija Popovic
Reirradiation is increasingly used, but its safe application requires accurate evaluation of cumulative doses to organs at risk. Methods of cumulative dose evaluation vary widely, from simple summation of prescription doses to complex three-dimensional (3D) dose summation methodologies, yet best practices remain undefined. This guidance, endorsed by the ESTRO Reirradiation Focus Group, provides detailed recommendations on the technical aspects of 3D dose summation; appropriate alternatives when it is unfeasible, suboptimal, or requires special considerations; and general guidance on uncertainty evaluation, resource management, and implications for treatment delivery. The writing group (n = 15) analysed scenarios ranging from full 3D dose summation to situations with incomplete data and unacceptable image registration, and developed recommendations through structured expert discussion and a two-step voting process. Key discussion points included: dose mapping (with rigid and deformable image registration), radiobiological corrections (particularly equieffective dose rescaling, such as EQD2Gy and BED), uncertainties, role of documentation, quality control, and peer review. Thirty-five statements reached consensus within both the writing group and the full ESTRO Physics Reirradiation Working Group (n = 34, 66 % response rate). Altogether, this guidance offers a practical framework for standardizing the technical aspects of cumulative dose evaluation to support clinical decision making and improve safety and effectiveness of reirradiation, while reducing institutional variability. It also highlights ongoing needs for research into advanced dose mapping, image registration, and integration of uncertainty analyses.

28 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
CTChristopher Thompson
Christopher Thompson
CPChristopher Pagett
Christopher Pagett
JLjohn lilley
john lilley
SSStina Svensson
Stina Svensson
KEKjell Eriksson
Kjell Eriksson
AAAne Appelt
Ane Appelt
(1) Background: The STRIDeR (Support Tool for Re-Irradiation Decisions guided by Radiobiology) planning pathway aims to facilitate anatomically appropriate and radiobiologically meaningful re-irradiation (reRT). This work evaluated the STRIDeR pathway for robustness compared to a more conservative manual pathway. (2) Methods: For ten high-grade glioma reRT patient cases, uncertainties were applied and cumulative doses re-summed. Geometric uncertainties of 3, 6 and 9 mm were applied to the background dose, and LQ model robustness was tested using α/β variations (values 1, 2 and 5 Gy) and the linear quadratic linear (LQL) model δ variations (values 0.1 and 0.2). STRIDeR robust optimised plans, incorporating the geometric and α/β uncertainties during optimisation, were also generated. (3) Results: The STRIDeR and manual pathways both achieved clinically acceptable plans in 8/10 cases but with statistically significant improvements in the PTV D98% (p < 0.01) for STRIDeR. Geometric and LQ robustness tests showed comparable robustness within both pathways. STRIDeR plans generated to incorporate uncertainties during optimisation resulted in a superior plan robustness with a minimal impact on PTV dose benefits. (4) Conclusions: Our results indicate that STRIDeR pathway plans achieved a similar robustness to manual pathways with improved PTV doses. Geometric and LQ model uncertainties can be incorporated into the STRIDeR pathway to facilitate robust optimisation.

26 December 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
FSFinbar Slevin
Finbar Slevin
SASophie Alexander
Sophie Alexander
SBSarah R Brown
Sarah R Brown
MCMatthew Carter
Matthew Carter
ACAnanya Choudhury
Ananya Choudhury
AHAnn M Henry
Ann M Henry
Introduction Prostate cancer (PCa) is the most common cancer in men. Recurrence may occur in up to half of patients initially treated with curative intent for high-risk localised/locally advanced PCa. Pelvic nodal recurrence is common in this setting, but no clear standard of care exists for these patients, with potential therapeutic approaches including stereotactic body radiotherapy (SBRT) to the involved node(s) alone, extended nodal irradiation (ENI) to treat sites of potential micrometastatic spread in addition to involved node(s) and androgen deprivation therapy with or without additional systemic anticancer therapies. Based on observational studies, ENI is associated with promising metastasis-free survival (MFS) compared with SBRT and appears to result in low rates of severe late toxicity. Methods and analysis Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer is a UK multicentre, open-label, phase III randomised controlled trial, which will deliver much needed, high-quality evidence of the impact on metastatic progression from ENI compared with SBRT in patients with PCa pelvic nodal recurrence. The trial will also evaluate the long-term toxicity of 5-fraction ENI compared with a standard 20-fraction schedule. The trail will randomise 480 participants in a ratio of 2:1:1 to SBRT, 5-fraction ENI or 20-fraction ENI from 35 to 40 UK radiotherapy sites over 4 years. Coprimary endpoints are MFS at 3 years and participant-reported late bowel toxicity at 3 years. Secondary endpoints include overall survival, biochemical progression-free survival, failure-free survival, patterns of failure, participant-reported/clinician-reported toxicity and health-related quality of life. Collection of blood and tissue samples will enable future evaluation of biomarkers of disease and toxicity and support stratification of salvage therapeutic approaches. Ethics and dissemination Ethical approval was obtained from NHS Health Research Authority, East of England – Cambridgeshire and Hertfordshire Research Ethics Committee (24/EE/0099). Trial results will be published in peer-reviewed journals and adhere to International Committee of Medical Journal Editors guidelines. Trial registration number ISRCTN11089334, registered on 23 September 2024.

15 July 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
JSJoep Stroom
Joep Stroom
MAMyriam Ayadi
Myriam Ayadi
AAAnja Aarberg
Anja Aarberg
VBVera Batel
Vera Batel
CCCemile Ceylan
Cemile Ceylan
NWNick West
Nick West
Despite the increasing frequency of reirradiation (reRT) in cancer treatment, a critical lack of reliable dose constraint data remains. This study addresses this gap by collating current reRT constraints used in clinical practice across multiple centers, facilitating the development of more consistent and safer reRT guidelines. A comprehensive survey collected data on reRT patient numbers, dose constraints, sources, and dose summation methods for 30 OARs. Information also included PRV margins, tissue recovery factors (TRF) with time intervals, α/β values, near-Dmax definitions, and dose constraints in EQD2Gy for first and reRT courses. The relative difference (XreRT) between cumulative reRT and first course constraints was calculated. Constraints with data from at least 7 centers were included for further analysis. A median of 6 % of treatments in 17 participating centers were reRT. Most centers derived reRT constraints from the literature (81 %) or first course constraints (68 %). In total 209 cumulative near-Dmax values for 19 OARs fulfilled n ≥ 7, yielding a median inter-center variation of 21 % (IQR). While α/β values were relatively consistent, substantial variations were seen in near-Dmax volume definition, TRF, and PRV margins. The median XreRT was 26 %, primarily attributed to the TRF which had a median value of 23 %. This multi-centre survey identified a concerning median inter-centre variation of 21 % in cumulative reRT dose constraints, indicating substantial heterogeneity in current clinical practices. Further prospective studies with rigorous and standardized dose reporting are essential to refine reRT guidelines, enhancing patient safety and treatment efficacy.

24 February 2022 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
CPChristopher Pagett
Christopher Pagett
JLjohn lilley
john lilley
RLRebecca Lindsay
Rebecca Lindsay
SSSusan Short
Susan Short
LMLouise Murray
Louise Murray
Re-irradiation may be used for recurrent glioblastoma (GBM) patients. In some cases Planning Target Volume (PTV) under-coverage is necessary to meet organ at risk (OAR) constraints. This study aimed to develop a Volumetric Modulated Arc Therapy planning solution for GBM re-irradiation including a means of assessing if target coverage would be achievable and how much PTV ‘cropping’ would be required to meet OAR constraints, based on PTV volume and OAR proximity. For 10 PTVs, 360°, 180°, two coplanar 180° and 180° + non-coplanar 45° arc arrangements were compared using 35 Gy in 10 fractions. Using the preferred arrangement, dose fall-off was modelled to determine the separation required between PTV and OAR to ensure OAR dose constraints were met, with data presented graphically. To evaluate the graph as an aid to planning, seven cases with overlap were replanned in two treatment planning systems (TPSs). There were no significant dosimetric differences between arc arrangements. 180° was preferred due to shorter treatment times. The graph, which indicated if 95% PTV coverage would be achievable based on PTV volume and OAR proximity, was employed in seven cases to guide planning in two TPSs. Plans were deliverable. Re-irradiation treatment planning can be challenging, especially when PTV under-coverage is necessary. 180° was considered optimal. To assist in the planning process, graphical guidance was produced to inform planners whether PTV under-coverage would be necessary and how much PTV ’cropping’ would be required to meet constraints during optimisation.

12 December 2025 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
CPChristopher Pagett
Christopher Pagett
JLjohn lilley
john lilley
COChristopher O’HAra
Christopher O’HAra
AAAne Appelt
Ane Appelt
LMLouise Murray
Louise Murray
CTChristopher Thompson
Christopher Thompson
Reirradiation is clinically challenging, requiring a balance between delivery of dose to tumour while respecting cumulative organ at risk (OAR) dose constraints. Standard prescriptions are often conservative, ignoring patient variability in achievable OAR doses. Isotoxic radiotherapy individualises treatment by delivering the highest equieffective dose in 2 Gy per fraction (EQD2Gy) while meeting OAR constraints. This technical feasibility study assessed isotoxic pelvic reirradiation using cumulative OAR constraints, the original dose distribution as background, and voxel-by-voxel EQD2Gy optimisation. Data from 30 patients previously treated with pelvic stereotactic body radiotherapy (SBRT) at three UK centres were included. OARs were delineated on both previous and reirradiation image sets and deformably registered. Previous dose was mapped to the current image set and used as background dose for SBRT planning, following published methods. Initial 25 Gy in five fractions (25 Gy/5#) plans were generated for all patients, with further isotoxic dose escalation conducted up to a maximum of 50 Gy (fraction number fixed) until cumulative EQD2Gy constraints were reached. For 25 of 30 patients, clinically acceptable isotoxic plans were obtained, with 23 exceeding the standard UK reirradiation prescription dose of 30 Gy/5#. The median isotoxic prescription was 42 Gy/5#, with four patient plans reaching the upper evaluated limit of 50 Gy. Vessels and the sacral plexus were most frequently dose limiting. This study highlighted the feasibility of isotoxic pelvic reirradiation and supports further investigation into automation and prediction models to streamline implementation in clinical practice.